Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19
San Diego, CA – August 4, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled “BCG: a therapeutic modality for COVID-19 and cancers” hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured distinguished clinicians […]
Nascent Biotech Announces Collaboration with Syracuse University – Advancing COVID-19 Research
San Diego, CA – July 28, 2020 – Nascent Biotech, Inc. (OTCQB.NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development of Pritumumab, a unique monoclonal antibody that binds to cell-surface vimentin, for potential use in COVID-19 treatment. Alison Patteson, an assistant professor of physics at Syracuse […]
Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19
San Diego, CA – June 17, 2020 – Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “the laboratory results were consistent with our Brain Cancer invitro studies and this is the […]
Nascent Biotech’s CEO Provides Corporate Updates on Phase I Brain Cancer Trial and COVID-19 Development Initiative on SNN Network
San Diego, CA – June 03, 2020— Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to provide a corporate update and summary with a recent interview the Company’s CEO, Sean Carrick, presented on SNN Network. The complete interview may be seen on the SNN Network at https://www.youtube.com/watch?v=bq-iWU9Ss_E&t=93s. Mr. Carrick indicates,” As […]
Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug
San Diego, CA – May 27, 2020— Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer. The study will employ Nascent’s monoclonal, antibody, Pritumumab (“PTB”) […]
Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19
San Diego, CA – May 12, 2020 – Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, today announced they have […]
